Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function by Berasain, C. (Carmen) et al.
Expression of Wilms’ Tumor Suppressor in the Liver
With Cirrhosis: Relation to Hepatocyte Nuclear
Factor 4 and Hepatocellular Function
Carmen Berasain,1 Jose´-Ignacio Herrero,1 Elena R. Garcı´a-Trevijano,1 Matı´as A. Avila,1 Juan Ignacio Esteban,2
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The Wilms’ tumor suppressor WT1 is a transcriptional regulator present in the fetal but not
in the mature liver. Its expression and functional role in liver diseases remains unexplored. In
this study, we analyzed WT1 expression by reverse-transcription polymerase chain reaction
(RT-PCR) and by immunohistochemistry in normal and diseased livers. In addition, we
performed in vitro studies in isolated rat hepatocytes to investigate WT1 regulation and
function. We detected WT1 messenger RNA (mRNA) in 18% of normal livers, 17% of
chronic hepatitis with minimal fibrosis, 49% of chronic hepatitis with bridging fibrosis, and
71% of cirrhotic livers. In cirrhosis, WT1 immunoreactivity was localized to the nucleus of
hepatocytes. WT1 mRNA abundance correlated inversely with prothrombin time (P .04)
and directly with serum bilirubin (P .002) and with the MELD score (P .001) of disease
severity. In rats, WT1 expression was present in fetal hepatocytes and in the cirrhotic liver
but not in normal hepatic tissue. In vitro studies showed that isolated primary hepatocytes
express WT1 when stimulated with transforming growth factor  (TGF-) or when the cells
undergo dedifferentiation in culture. Moreover, we found that WT1 down-regulates hepa-
tocyte nuclear factor 4 (HNF-4), a factor that is essential to maintain liver function and
metabolic regulation in the mature organ. Hepatic expression of HNF-4 was impaired in
advanced human cirrhosis and negatively correlated with WT1 mRNA levels (P .001). In
conclusion, we show that WT1 is induced by TGF- and down-regulates HNF-4 in liver
cells. WT1 is reexpressed in the cirrhotic liver in relation to disease progression and may play
a role in the development of hepatic insufficiency in cirrhosis. (HEPATOLOGY 2003;38:148-157.)
The presence of portal hypertension and the devel-opment of hepatic insufficiency determine theevolution and prognosis of cirrhosis. Although
there is abundant information pertaining to the cellular
and molecular basis of fibrogenesis, the factors and mech-
anisms leading to the decay of liver function are not well
understood. In cirrhotic patients, hepatic insufficiency is
frequently associated with reduced liver weight,1 but the
breakdown of hepatic functions cannot be merely as-
cribed to a diminished parenchymal mass. A functional
defect of existing hepatocytes rather than a reduced num-
ber of liver cells appears to be the main cause of hepato-
cellular failure in cirrhosis. In fact, recent data have shown
that the failing cirrhotic liver is characterized by the pres-
ence of a high proportion of hepatocytes that do not ex-
press gene products that typify the mature hepatocyte
phenotype.2 The molecular changes that promote the loss
of differentiated hepatocellular functions in cirrhosis still
remain undefined.
The Wilms’ tumor suppressor WT1 is a developmen-
tally regulated transcriptional factor that plays a critical
role in organ-specific differentiation (reviewed in Eng-
lert,3 Menke et al.,4 Lee and Haber,5 and Scharnhorst et
al.6). The WT1 gene encodes a 3.5-kb transcript, which
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can undergo alternative splicing, resulting in 4 isoforms
differing by the presence or absence of exon 5 (plus or
minus exon 5 isoforms) or 3 amino acids encoded by the
3 end of exon 9 (plus or minus KTS isoforms). WT1
possesses an N-terminal transactivational domain and a
carboxy terminus containing 4 contiguous Cys2-His2
zinc fingers mediating sequence-specific DNA binding.
WT1 is a multifaceted gene that can transcriptionally reg-
ulate a diversity of growth and differentiation-related
genes. It can also bind messenger RNA (mRNA) and has
been proposed to participate in the splicing apparatus.7-9
WT1 expression is both developmental and tissue re-
stricted, being detected in fetal liver4,6 but not in normal
adult liver.10,11 In the present work, we have investigated
the expression of WT1 in hepatic tissue of patients with
liver diseases and the relationship of this factor to hepato-
cellular function.
Patients and Methods
Patients. We obtained specimens of liver tissue
from 4 groups of subjects: (1) control individuals (n
28; 19 male; mean age, 50.8; range, 18-73 years) with
normal or minimal changes in the liver. We collected
tissue samples at surgery (17 cases) of digestive tumors
or from percutaneous liver biopsy performed because
of small changes in liver function tests (10 cases) or to
confirm complete response of chronic hepatitis C to
interferon therapy (1 case); (2) chronic hepatitis C with
no or only portal fibrosis (score12 F0-F1) (n  24; 17
male; mean age, 39.2; range, 19-61 years); (3) chronic
hepatitis C with bridging fibrosis (score F3) (n  39;
25 male; mean age, 50.6; range, 23-69 years); and (4)
cirrhosis (n 73; 50 male; mean age, 56; range, 20-77
years). In 46 patients of the last group, we obtained the
sample at the time of liver transplantation and in 3
cases at operation for resection of hepatocellular carci-
noma. Cirrhosis was due to hepatitis C virus infection
in 44 cases, alcohol abuse in 18 cases, hepatitis B virus
infection in 6 cases, hemochromatosis in 4, and cryp-
togenic in 1 case. Associated hepatocellular carcinoma
was present in 13 cirrhotic patients.
RNA Isolation and Reverse-Transcription Polymer-
ase Chain Reaction. We extracted total RNA using TRI
Reagent (Sigma, St. Louis, MO). We treated 2 g of
RNA with DNaseI (Gibco-BRL, Paisley, United King-
dom) prior to reverse transcription with M-MLV Re-
verse Transcriptase (Gibco-BRL) in the presence of
RNaseOUT (Gibco-BRL) and used one tenth of the
cDNA preparation for each polymerase chain reaction
(PCR). We designed all primers to distinguish between
genomic and cDNA amplification (Table 1) and se-
quenced all PCR products to confirm the specificity. We
included in the study only the samples with a comparable
amplification of -actin mRNA.
Real-Time Quantitative PCR. We undertook quan-
titative real-time RT-PCR using a LightCycler (Roche
Diagnostics GmbH, Mannheim, Germany) and the LC-
DNA Master SYBR Green I mix in 1:200 dilution of
cDNA. To monitor the specificity, we analyzed the final
PCR products by melting curves and electrophoresis. We
calculated the level of expression of the different genes by
plotting the threshold cycle on the standard curve ob-
tained after amplification of serial dilution of a plasmid
containing the corresponding full length cDNA. Results
were normalized according to -actin quantitation in the
same sample. Only those human samples with a high yield
of RNA were used for quantitation of WT1 and hepato-
cyte nuclear factor 4 (HNF-4) mRNA.
Table 1. Primers Used in This Study
Gene Sense Primer (5-3) Antisense Primer (5-3)
-Actin (human) AGCCTCGCCTTTGCCGA CTGGTGCCTGGGGCG
-Actin (rat) CAACCTCCTTGCAGCTC CTGGTGCCTAGGGCG
Aldolase B CAGAGCATTGTTGCCAATG GAGAGGCCATCAAGCCCTTG
HNF-4 CTGCACCCTCACCTGATGC GGCTGGGGGATGGCAGAG
MAT2A ATGCTGTCCTTGATGCAC GCGTAACCAAGGCAATG
Rat seroalbumin ATGAAGTGGGTAACC TGTCAGACTCTGTGC
Vimentin TCCTACCGCAGGATGTTCGG GCACCTTGTCGATGTAGTTGG
WT1
TD (touchdown) (exon 8-exon 10) GTGAGAAACCATACCAGTGTG GTGCAAGGAGGTATGTACAT
Multiplex (exon 2-exon 10-2) ATGAGGATCCCATGGGCCAGCA GCGCCAGCTGGAGTTTGGTC
Real time PCR
exon 1-exon 4 (human) AGCCCGCTATTCGCAATCAGG GTGGCTCCTAAGTTCATCTG
exon 4-exon 7 (human) GGAATCAGATGAACTTAGGAG CGTTTCTCACTGGTCTCAGATGCCG
exon 4-exon 7 (rat) GGAACCAGATGAACCTCGGAG CGCTTCTCACTGGTTTCAGATGCTG
exon 8-exon 10-2 (human) GTGAGAAACCATACCAGTGTG GCGCCAGCTGGAGTTTGGTC
Phosphothiorated oligonucleotides CAGCAAATGGGCTCCGAC GTCGGAGCCCATTTGCTG
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Immunohistochemistry. We dewaxed the paraffin-em-
bedded sections in xylene and rehydrated them in decreasing
grades of ethanol. Antigenic unmasking was accomplished
by boiling in 10 mmol/L citrate buffer, pH 7. We blocked all
preparations with 10% of goat normal serum and 0.3% of
oxygen peroxide, and the samples from cultured hepatocytes
were additionally blocked with the avidin-biotin blocking kit
(Vector Labs., Burlingame, CA). We applied the primary
antibody anti-WT1 C-19 (Santa Cruz, Santa Cruz, CA) or
preimmune rabbit IgG (Santa Cruz) or phosphate-buffered
saline (as negative controls) overnight, followed by the sec-
ondary biotinylated anti-rabbit antibody (Vector Labs.) and
the streptavidin-biotinylated-HRP (Amersham, Bucking-
hamshire, United Kingdom) for 45 minutes each. We used
DAB (Dako, Carpinteria, California) to visualize the perox-
idase activity. Samples were counterstained in Mayer’s he-
matoxylin and mounted in Depex. The specificity of the
signal obtained with the anti-WT1 antibody was further
supported by the following observations: PLC and HepG2
cell lines that were positive for WT1 expression, as assayed by
RT-PCR, also proved positive by immunocytochemistry us-
ing this anti-WT1 antibody. When WT1 expression was
negative by RT-PCR, such are the cases of Hep3B and
HuH7 cells; immunostaining using this antibody was also
negative. Upon transfection of HuH7 cells with a WT1-
expressing vector, a specific signal was detected when stained
with this anti-WT1 antibody. Additionally, immunostain-
ing of rat fetal kidney with this anti-WT1 antibody gave a
strong signal in the podocyte layer of developing glomeruli,
the cell type that expresses highest levels of WT1 protein in
this organ during development.
Animals. We performed all experimental procedures
in conformity with our institution’s guidelines for the use
of laboratory animals. Cirrhosis was induced with CCl4 as
previously described.13
Isolation and Culture of Rat Hepatocytes. We iso-
lated and cultured adult rat hepatocytes as described pre-
viously.14 After 3 hours of culture, we again fed the
hepatocytes with medium containing 0.5% fetal calf se-
rum in the presence or absence of 4 mmol/L S-adenosyl-
methionine (SAM). Treatment of hepatocytes with
transforming growth factor  (TGF-) was performed by
addition of 5 ng/mL of human recombinant TGF-1
(Roche Diagnostics) 24 hours after seeding.
Hepatocytes from 20-day-old fetal rats (Wistar) were
isolated by collagenase disruption as previously described
(2.5  106 cells/fetus).15 The cells were plated on non-
coated plastic dishes in arginine-free medium 199 (a se-
lective medium for liver parenchymal cell survival and
growth), supplemented with ornithine (200 mol/L), fe-
tal bovine serum (10%), penicillin (120 g/mL), and
streptomycin (100 g/mL). The medium was changed 4
hours after seeding.
Transient Transfection of Rat Hepatocytes. We
seeded hepatocytes 24 hours before transfection with the
Tfx-50 reagent (Promega, Madison, WI) according to the
manufacturer’s instructions, and we transfected the cells
in duplicate with an equimolar mixture of pCB6 plasmids
encoding the 4 isoforms of WT1 (characterized by the
presence or absence of the splice inserts, exon 5 and KTS)
kindly provided by Dr. Jochemsen (Leiden University
Medical Center, Leiden, The Netherlands). Transfection
efficiency of the equimolar mixture of the 4 WT1 iso-
forms was monitored by RT-PCR analysis using specific
primers that discriminated these isoforms. The relative
expression of the corresponding mRNA was similar in all
experiments. In other experiments, we transfected hepa-
tocytes with 1 mmol/L of either sense or antisense phos-
phothiorated WT1 oligonucleotides (Table 1).
CAT Assay. We transfected HuH7 cells in quadrupli-
cate using Tfx-50 (Promega) with the pCAT Enhancer
plasmid and the pCAT Dual WT1 promoter plasmid
encompassing 1.2 kb of the 5 region of human WT1
gene16 (kindly provided by Dr. Fraizer from the MD
Anderson Cancer Center in Houston, Texas). We mea-
sured the CAT activity using the CAT ELISA (Roche)
after 18 hours of treatment with 5 ng/mL of TGF-. To
ascertain the specific effect of TGF- on WT1 promoter
transactivation, hepatocytes were also transfected with
other constructs in which the reporter gene was under the
control of either rat methionine adenosyltransferase 1A14
(MAT1A) (1.4 kb of the 5 region of this gene) or cyto-
megalovirus (CMV) promoters.
Statistical Analysis. Comparison of the distribution
of WT1 expression was based on Fisher exact test and 2
test as appropriate. Data for each continuous variable
were examined with the Shapiro-Wilk W test to deter-
mine whether assumptions of normality were valid. Nor-
mally distributed data were compared among groups
using an independent Student’s t test and 1-way analysis
of variance. Data not normally distributed were compared
using the Kruskal-Wallis and the Mann-Whitney tests.
Correlation was assessed by Spearman’s or Pearson’s cor-
relation coefficients. All the tests were 2-sided, and the
significance level was 5%. Descriptive data for continuous
variables are reported as means  SD or as medians and
interquartile range.
Results
WT1 Expression in Normal Liver Tissue and in
Chronic Liver Diseases. Using touchdown PCR, WT1
mRNA was detected in only 18% of control livers and
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17% of chronic hepatitis with fibrosis stage F0-F1. In
contrast, 49% of patients with chronic hepatitis with fi-
brosis stage 3 (P .01 vs. controls) and 71% of cirrhotic
patients (P .001 vs. controls) showed WT1 expression
(Fig. 1A). These results were confirmed by multiplex PCR
with simultaneous amplification of WT1 and aldolase B
(Fig. 1B). In these studies, we used human kidney (a tissue
that normally expresses WT1) as a positive control. WT1
mRNA was not detected in peripheral mononuclear cells
from any of the patients studied.
We performed 2 independent PCRs to amplifyexon
5 and KTS isoforms. The two exon 5 isoforms were
found in 40% of WT1-positive control livers (2 out of 5)
and in 85% of WT1-positive cirrhotic livers (22 out of
26) (P .062). In the remaining WT1-positive samples,
onlyexon 5 could be amplified. With respect toKTS
isoforms, the two variants were present in all the samples
tested.
Immunohistochemical studies showed no WT1 im-
munoreactivity in normal liver tissue. By contrast, in the
cirrhotic liver, many hepatocytes showed intense WT1
staining. An intermediate level of expression was found in
scattered hepatocytes in samples with chronic hepatitis.
WT1 immunoreactivity localized at the nuclei of hepato-
cytes, showing a distinct nucleolar accumulation in some
cells (Fig. 1C).
WT1 mRNA Levels in Cirrhosis: Relationship to
Hepatocellular Function. In 42 samples (19 control
and 23 cirrhosis), we determined WT1 mRNA levels by 3
different real-time PCR reactions (Table 1). Similar re-
sults were obtained in the 3 assays, and those correspond-
ing to exon 4-exon 7 PCR are shown in Fig. 2. We found
that none of the control livers that tested negatively
using touchdown PCR was positive by real-time PCR,
whereas 7 out of 9 cirrhotic livers with undetectable WT1
mRNA by the first method were positive by real-time
PCR. This indicates that WT1 mRNA can be found
in almost all cirrhotic livers when sensitive PCR methods
are used.
The values of WT1 mRNA were significantly higher in
cirrhosis than in controls (73.1 WT1 copies per 106 cop-
ies of -actin; range, 16-160.9 vs. 0.00; range, 0.00-0.00,
respectively; P  .001) and in patients with cirrhosis
Child-Pugh B or C (149.95; range, 72.69-317.59) than
in Child-Pugh A (14.31; range, 0.7-32.67; P  .001)
(Fig. 2A). We found that the level of WT1 mRNA corre-
lated with total bilirubin (r  0.62, P  .002) and in-
versely with prothrombin time (r  0.45, P  .04). A
significant correlation (r  0.64, P  .001) was found
with the Model for End-Stage Liver Disease (MELD)17
score (Fig. 2B), indicating a direct relationship between
WT1 expression and disease severity.
Fig. 1. Expression of WT1 in the
liver of patients and controls. (A)
Prevalence of WT1 mRNA (as deter-
mined by touchdown RT-PCR) in nor-
mal liver tissue (controls), patients
with chronic hepatitis with fibrosis
stage 0-1 (F0-F1), chronic hepatitis
fibrosis stage 3 (F3), and cirrhosis.
(B) An example of multiplex PCR of
WT1 and aldolase B (Aldo B) in
control and cirrhotic livers and in
3 independent samples of normal
kidneys (a tissue that normally
expresses WT1). (C) Immunohisto-
chemical detection of WT1 protein in
normal liver and liver from patients
with chronic hepatitis and cirrhosis.
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WT1 in the Cirrhotic Liver of Rats. The transcrip-
tional activation of WT1 that we observed in the human
fibrotic liver was paralleled by our findings in rats with
experimental cirrhosis. Utilizing multiplex PCR we
found that, although WT1 mRNA was undetectable in
the normal rat liver, a clear amplification band was ob-
tained in CCl4-induced cirrhosis and in fetal rat hepato-
cytes (Fig. 3A). In these studies, we used rat kidney (a
tissue that normally expresses WT1) as a positive control.
In addition, real-time PCR (with exon 4-exon 7 primers)
demonstrated that the content of WT1 mRNA in liver
tissue was significantly higher in cirrhotic animals than in
controls (25.18 11.46 vs. 2.69 2.62, respectively, P
 .001) (Fig. 3B).
Induction of WT1 by TGF-. TGF- is an essential
factor in liver fibrogenesis,18 and it is also a negative signal
for hepatocellular differentiation.19 Thus, we investigated
whether this cytokine could influence WT1 expression in
hepatocytes. We found that incubation of primary rat
hepatocytes with TGF- for 24 hours caused a significant
increase in the levels of WT1 mRNA (Fig. 4A and B).
This effect was associated with induction of vimentin, a
marker of hepatocellular dedifferentiation (Fig. 4A). As
shown in Fig. 4C, TGF-–stimulated WT1 expression is
completely abolished by the transcription inhibitor acti-
nomycin D or by the translation inhibitor cycloheximide,
indicating that TGF- induces WT1 by a transcriptional
mechanism requiring protein synthesis. Although some of
the biologic actions of TGF- are mediated by increasing
the overall oxidative state of treated cells and enhancing
the production of H2O2,20 this effect does not seem to
mediate WT1 induction because neither catalase nor des-
ferrioxamine could abrogate the expression of WT1 after
stimulation with TGF- (Fig. 4D).
To analyze the effect of TGF- on WT1 transcrip-
tion, we performed CAT assays in HuH7 cells (that do
not express WT1) transfected with a plasmid contain-
ing the reporter gene under the control of the dual
WT1 promoter.16 This construct encompasses 1.2 kb
of the human WT1 promoter and includes the minimal
promoter region capable of initiating transcription, as
well as potential regulatory elements. We found that, at
18 hours after transfection, CAT activity was more
than 3 times higher in the presence of TGF- than in
its absence (Fig. 4E), indicating that TGF- enhances
WT1 transcription by activation of WT1 promoter.
When hepatocytes were transfected with reporter plas-
mids under the control of MAT1A14 or CMV promot-
ers— genes that do not respond to TGF-—no
stimulatory effect was observed after TGF- treatment
(Fig. 4E), thus supporting the specificity of the effect
observed on WT1 promoter.
Fig. 2. Quantitation of WT1 mRNA levels by real time PCR in the liver
of cirrhotic patients and liver function. (A) WT1 mRNA values in control
livers and cirrhosis Child-Pugh A, B, or C. (B) Correlation between WT1
mRNA values and MELD score in cirrhosis.
Fig. 3. WT1 mRNA in the liver of
normal and cirrhotic rats. (A) Multi-
plex PCR amplification of WT1 and
aldolase B (Aldo B) in the liver of
normal rats, cirrhotic rats, and iso-
lated fetal hepatocytes (FH). Rat
kidney (K) was used as positive con-
trol. (B) Quantitative real-time PCR
for WT1 mRNA in the liver of normal
and cirrhotic rats.
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Expression of WT1 and Hepatocyte Dedifferentia-
tion. Cultured hepatocytes undergo a time-dependent
process of dedifferentiation with decreased levels of
HNF-4 and serum albumin mRNAs and up-regulation of
vimentin expression (Fig. 5A). We observed that these
changes take place in parallel with an activation of WT1
expression. Thus, WT1 mRNA was undetectable imme-
diately after plating and increased progressively with time
in culture (Fig. 5B). Similarly, immunocytochemical
analysis showed no WT1 protein in hepatocytes cultured
for 6 hours, whereas WT1 immunoreactivity could be
clearly seen at 24 hours in the cytoplasm, at 72 hours in
both cytoplasm and nucleoli, and after 96 hours only in
nucleoli (Fig. 5C). Interestingly, when cells were incu-
bated from the onset of culture (t 0) in the presence of
SAM, a molecule known to maintain the differentiated
phenotype of hepatocytes in culture,14 WT1 induction
was prohibited, and the fall of albumin expression was
reduced (Fig. 5D). These effects of SAM were also ob-
served after 96 hours of treatment, the last time point
tested (data not shown).
Given that WT1 induction appeared to be associated
with acquisition of a dedifferentiated hepatocellular phe-
notype, we analyzed whether WT1 could influence the
expression of HNF-4 and methionine adenosyltransferase
2A (MAT2A) because the former is a key factor in main-
taining metabolic functions in the mature parenchymal
liver cells and the latter is induced upon dedifferentiation
of hepatocytes.14 We found that transfection of primary
hepatocytes with an equimolar mixture of the 4 WT1
isoforms induced a decrease of HNF-4 mRNA at 48
hours (12,127  2,806 copies of HNF-4/103 copies of
-actin in control cells, with a 31.25% reduction upon
WT1 transfection) while simultaneously stimulating the
expression of MAT2A (136 40 copies of MAT2A/103
copies of -actin in control cells, with a 43.75% induc-
tion upon WT1 transfection) (Fig. 6A). In confirmation
of these findings, we observed up-regulation of HNF-4
and down-regulation of MAT2A in TGF-–treated pri-
mary hepatocytes when WT1 transcription was inhibited
using anti-sense oligos (Fig. 6B).
HNF-4 Expression in Normal and Cirrhotic Hu-
man Liver. As mentioned above, HNF-4 plays a central
role in the preservation of liver functions. This fact, to-
gether with our present observations on the potential role
of WT1 on HNF-4 gene expression down-regulation, led
Fig. 4. Induction of WT1 by TGF-. (A and B) Rat hepatocytes were cultured for 24 hours and then maintained in culture for an additional 24
hours in the absence (Ctrol) or in the presence of TGF-. The Fig. (A) shows induction of WT1 and vimentin expression (Vim) by TGF-. Induction
of WT1 mRNA is demonstrated by touchdown PCR with exon 8-exon 10 primers (A) and by quantitative real-time PCR with exon 4-exon 7 primers
(B). The graph represents the results of 3 independent experiments performed in triplicate. (C) Effect of actinomycin-D (Act-D) (5 g/mL) and
cycloheximide (CHX) (10 g/mL) in the induction of WT1 by TGF- (hepatocytes were cultured for 24 hours and then treated as indicated for 16
hours with TGF- in the absence or presence of Act-D or CHX). (D) Effect of catalase (1,000 U/mL) and desferrioxamine (1 mmol/L) in the induction
of WT1 by TGF- (hepatocytes were cultured for 24 hours and then treated for 24 hours with TGF- in the absence or presence of catalase or
desferrioxamine). (E) HuH7 cells were transfected with a construct harboring the dual WT1 promoter coupled to a CAT reporter gene and were treated
with TGF-. CAT activity of control and treated cells is represented as fold change with respect to the activity of pCAT-enhancer control plasmid.
Transfections with plasmids harboring the reporter gene under the control of MAT1A or CMV promoters were performed to control for the specificity
of WT1 response to TGF- treatment. Figure represents the mean of 3 independent experiments in quadruplicate.
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Fig. 5. WT1 expression in cultured
primary rat hepatocytes: relationship
to hepatocellular differentiation. (A)
RT-PCR amplification bands for WT1,
HNF-4, rat serum albumin (RSA),
and vimentin in cultured hepato-
cytes at different times of culture (0,
48, and 72 hours). (B) WT1 mRNA
levels by real-time PCR in hepato-
cytes at different times of culture. *P
 .05, **P  .001 for comparison
with basal values. Results of 4 in-
dependent experiments in duplicate
are represented. (C) Immunohisto-
chemical detection of WT1 in cul-
tured hepatocytes at different times
of culture. (D) Effect of SAM on the
induction of WT1. RT-PCR amplifica-
tion bands for WT1, rat serum albu-
min (RSA), and -actin in
hepatocytes cultured in the pres-
ence or absence of SAM (4 mmol/L)
for 72 hours.
Fig. 6. Effect of WT1 on HNF-4 and MAT2A expression. (A) HNF-4 and MAT2A mRNA amplification bands in rat hepatocytes 48 hours after
transfection with an equimolecular mixture of the 4 WT1 isoforms (WT1) or empty pCB6 plasmids (pCB6). A representative example and the results
of 3 independent experiments are shown. (B) HFN4 and MAT2A mRNA amplification bands in TGF-–treated rat hepatocytes transfected with sense
or antisense WT1 oligonucleotides. Hepatocytes were cultured for 24 hours and then transfected with either sense or antisense WT1 oligonucleotides
and treated with TGF- (added to the medium at the time of transfection) for another 24 hours. A representative example and the results of 3
independent experiments are shown. In both A and B, bars represent the percentage change in the number of copies of HNF-4 or MAT2A per 103
copies of -actin with respect to cells transfected with empty plasmid or sense oligonucleotide, with this value being taken as 100%.
154 BERASAIN ET AL. HEPATOLOGY, July 2003
us to measure HNF-4 mRNA values in cirrhotic livers.
Real-time PCR analysis showed that the levels of HNF-4
mRNA were significantly reduced in patients with cirrho-
sis Child-Pugh B or C as compared with control livers
(P  .01) (Fig. 7A). Expression levels of HNF-4 in the
liver of patients with cirrhosis Child-Pugh A were not
distinguishable from control livers (Fig. 7A), indicating
that loss of HNF-4 expression was associated with the
progression of the disease. In fact HNF-4 mRNA values
correlated inversely and significantly with the MELD
score of disease severity (r0.60, P .003). Interest-
ingly, we found that the level of WT1 gene expression
inversely correlated with that of HNF-4 in the liver of
control and cirrhotic patients (r0.54, P .001) (Fig.
7B). As shown in Fig. 7B, all patients (10 out of 10) with
more than 100 copies of WT1 mRNA/106 copies -actin
in the liver manifested reduced hepatic expression of
HNF-4 (100 copies/103 copies -actin mRNA). How-
ever, there were 4 control livers and 2 cirrhotic livers that,
although showing no expression of WT1, expressed re-
duced levels of HNF-4 (Fig. 7B). The biologic signifi-
cance of low HNF-4 expression in some noncirrhotic
livers is not known and is currently under investigation in
our laboratory.
Discussion
Hepatocytes are highly differentiated cells that fulfill a
great number of biosynthetic, metabolic, detoxifying, and
secretory activities. Accomplishment of all these functions
depends on the coordinated expression of a vast array of
genes determining the mature hepatocyte phenotype.
This specific pattern of gene expression is altered in cir-
rhosis. Thus, it has been shown that, although 60% of
hepatocytes express factor VII mRNA in normal hepatic
tissue, less than 4% of liver cells are positive for this tran-
script in advanced cirrhosis.2 The cellular and molecular
mechanisms responsible for these transcriptional changes
remain poorly understood. Our findings point to WT1 as
a potential factor implicated in the impairment of hepa-
tocellular function that occurs during the progression of
cirrhosis.
WT1 has been shown to be involved in cell differenti-
ation processes, although its effects may differ according
to the cell system analyzed.21-26 In hepatocytes, the pres-
ence of WT1 appears to denote functional immaturity in
that we observed that this transcriptional regulator is ex-
pressed in the fetal hepatocyte but not in the mature
parenchymal cell. Supporting this idea, WT1 immunore-
activity was found in hepatocyte precursors but not in
fully differentiated parenchymal cells in a model of liver
regeneration from undifferentiated progenitor cells.27
The negative role of WT1 on hepatocellular differen-
tiation is supported by our in vitro findings showing the
following: (1) WT1 accumulates in cultured hepatocytes
in parallel with diminished expression of serum albumin
and HNF-4 and up-regulation of vimentin; (2) WT1 is
down-regulated in cultured hepatocytes by SAM, a com-
pound known to maintain the differentiated hepatocyte
phenotype in culture; (3) overexpression of WT1 induces
down-regulation of HNF-4 and up-regulation of
MAT2A, a marker of hepatocyte dedifferentiation; and
(4) silencing of WT1 results in up-regulation of HNF-4
and down-regulation of MAT2A.
The influence of WT1 on HNF-4, a previously unrec-
ognized phenomenon, is of particular importance because
of the critical role of HNF-4 not only in hepatocyte dif-
ferentiation during mammalian liver development but
also because this factor is essential to maintain liver func-
tion and metabolic regulation in the mature organ.28 This
Fig. 7. Expression of HNF-4 in the liver of patients and controls. (A)
HNF-4 mRNA levels were quantitated by real-time PCR in control livers
and cirrhosis Child-Pugh A, B, or C. (B) Correlation between WT1 and
HNF-4 mRNA levels in controls and cirrhosis.
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paper shows, to our knowledge for the first time, that
HNF-4 expression is impaired in livers with advanced
cirrhosis (Child-Pugh score B and C). These cases are
precisely those in which WT1 is strongly stimulated.
Down-regulation of HNF-4 gene expression may be rel-
evant to understand the mechanisms involved in the loss
of hepatocellular function in the diseased liver, given the
central role played by this transcription factor in the
maintenance of liver-specific gene expression.29,30 As
mentioned previously, hepatic WT1 mRNA levels corre-
late inversely both with HNF-4 expression and with pa-
rameters of liver function such as prothrombin time and
serum bilirubin. Moreover, WT1 mRNA values correlate
directly with the severity of liver disease as estimated by
the MELD score. Taken together, our in vitro and in vivo
data point to the concept that WT1 is a developmental-
restricted factor, which is reexpressed in cirrhosis, that
may negatively affect hepatocyte differentiation and func-
tion possibly by influencing HNF-4 expression. Thus,
WT1 may be implicated in the progression of cirrhosis to
advanced stages of hepatic insufficiency.
Interestingly, in cirrhosis, WT1 immunoreactivity lo-
calizes to the nuclei of hepatocytes, showing a distinct
nucleolar accumulation in some cells. However, in cul-
tured liver cells, WT1 is initially seen in the cytoplasm
and later on in nucleoli. In addition to ribosomal biogen-
esis, nucleoli also seem to be involved in the transport and
turnover of specific mRNA.31 These data are compatible
with previous studies showing that WT1 can localize in
the cytoplasm or in the nucleus depending on its phos-
phorylation status.32 Thus, the distribution of WT1 in
hepatocyte nuclei appears to reflect the ability of WT1 to
bind not only to DNA but also to RNA,7-9 suggesting its
participation in the organization of subnuclear architec-
ture and regulation of transcription.
The association between WT1 and the presence of liver
fibrosis both in rats and in man led us to investigate
whether TGF-, a key profibrogenic cytokine, could ac-
tivate WT1 gene expression. Our data show that TGF-
enhances WT1 transcription by stimulating WT1 pro-
moter. This novel effect of TGF- may be implicated in
its activity as a negative signal for hepatocyte differentia-
tion.19 In addition to TGF-, other factors could partic-
ipate in the induction of WT1 in cirrhosis. Hypoxia,
which occurs in the cirrhotic liver by diverse mecha-
nisms,33 has been shown to activate WT1 in the ischemic
adult heart.34 Because WT1 is induced by profibrogenic
stimuli, its stimulation may be a link between fibrosis
progression and impairment of hepatocellular function in
cirrhosis. In summary, WT1 is a TGF-–inducible gene
expressed in fibrotic livers that may play a role in the
evolution of cirrhosis to advanced stages of hepatic insuf-
ficiency.
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